CSPC PHARMA: SYS 6036 injection has been approved for clinical trials in China
I'm PortAI, I can summarize articles.
CSPC PHARMA announced that its developed SYS 6036 injection has been approved by the National Medical Products Administration of China for clinical trials. This drug is a humanized monoclonal antibody primarily used for tumor immunotherapy, applicable to various cancers, including melanoma and non-small cell lung cancer. The research and development follow the biosimilar research guidelines, demonstrating a high degree of similarity in quality, safety, and efficacy compared to the original drug
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments